← All indications
Hepatitis B, Chronic
INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
Drugs by status
Approved for this indication (7)
Phase 4 trials (36)
- vitamin d3
- avatrombopag
- vitamin e
- evogliptin
- prednisone
- glycyrrhizin
- empagliflozin
- etravirine
- fufang biejia ruangan
- aldesleukin
- cyanocobalamin
- interferon alpha-2a
- ozone
- magnesium isoglycyrrhizinate
- pegylated-interferon
- polyene phosphatidylcholine
- hepatitis b vaccine (recombinant)
- ribavirin
- sofosbuvir
- emtricitabine
- velpatasvir
- thiamine
- poly-iclc
- pioglitazone
- essential phospholipids
- oxymatrine
- dapagliflozin
- pyridoxine
- sargramostim
- riboflavin
- +6 more
Phase 3 trials (8)
Phase 2 trials (79)
Phase 1 trials (59)
- hb-110
- dv-601
- gc1102
- ethinyl estradiol
- rosuvastatin
- rifampin
- warfarin
- nvr 3-778
- peginterferon lambda-1a
- ppdpsc18
- ro7020322
- ro7062931
- tg1050
- digoxin
- itraconazole
- vitamin k
- as01
- midazolam
- hydrochlorothiazide
- simeprevir
- omeprazole
- esomeprazole
- apg-1387
- levonorgestrel
- cetrelimab
- chad155-hii-hbv
- liocyx
- jnj-440
- edp-514
- abi-h3733
- +29 more
Other trials (31)
- metformin
- efavirenz
- spirulina
- abacavir
- guifu erxian
- ganbi
- ganji
- taohong huazhuo
- zimu dan
- amlodipine
- nevirapine
- vitamin c
- atorvastatin
- polyherbal
- chaihu shugan san
- ge xia zhu yu
- xiaoyao
- yiguan
- abatacept
- ursolic acid
- human fecal microbiota
- zidovudine
- adenosma glutinosum
- eclipta prostrata
- fuzilizhong
- jinkui shenqi
- yinchengao
- ganlu
- phyllanthus
- rilpivirine
- +1 more
Organizations
Organization Involved with Phase 4 Indications (135)
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- Roche
- Merck
- Sanofi
- Novartis
- Beijing Kawin Technology Share-Holding Co., Ltd.
- Bukwang Pharmaceutical
- Dong-A Pharmaceutical
- GlaxoSmithKline
- Hannover Clinical Trial Center GmbH
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- New Discovery LLC
- SciClone Pharmaceuticals
- Shineway Pharmaceutical Co.,Ltd
- Chong Kun Dang Pharmaceutical
- Daewoong Pharmaceutical Co. LTD.
- IlDong Pharmaceutical Co Ltd
- Foundation for Liver Research
- French National Agency for Research on AIDS and Viral Hepatitis
- Huazhong University of Science and Technology
- Ajou University
- Hebei University
- Asian-Pacific Alliance of Liver Disease, Beijing
- Tzu Chi University
- Chang Gung University
- Changhua Christian Hospital
- Changi General Hospital
- Chiayi Christian Hospital
- Chung Shan Medical University
- Chungbuk National University
- +105 more
Organization Involved with Phase 3 Indications (32)
- Abivax S.A.
- Eisai
- Pharmasset
- Schering-Plough
- Grifols
- Institut Pasteur
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Sponsor GmbH
- Xiamen Amoytop Biotech Co., Ltd.
- Xintong Pharmacy Company
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Pittsburgh
- Central South University
- Clinical Research Organization, Dhaka, Bangladesh
- Jilin University
- Mahidol University
- University of Ottawa
- University of Bonn
- Mayo Clinic
- Bangladesh Medical University
- Wonju Christian Hospital
- Eulji University
- Janssen Pharmaceutica NV
- Ewha Womans University
- Biotest Pharmaceuticals
- Hopital Principal de Dakar Senegal
- Chonnam National University
- Tianyi medical instruments limited company
- +2 more
Organization Involved with Phase 2 Indications (68)
- PPD
- Achillion Pharmaceuticals
- Human Genome Sciences
- Green Cross Corporation
- Bausch Health Companies
- AstraZeneca
- Romark
- Alnylam Pharmaceuticals
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals
- Ascentage Pharma Group Inc.
- Ascletis Pharmaceuticals Co., Ltd.
- CHA Vaccine Institute Co., Ltd.
- FibroGen
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
- Henlix, Inc
- Hepatera Ltd.
- Ionis Pharmaceuticals, Inc.
- LG
- Parexel
- Qilu Pharmaceutical Co., Ltd.
- Shanghai Genomics, Inc.
- Spring Bank Pharmaceuticals, Inc.
- Sunshine Lake Pharma Co., Ltd.
- Tasly Pharmaceuticals, Inc.
- Vaxine Pty Ltd
- A2 Healthcare Taiwan Corporation
- Altimmune, Inc.
- Assembly Biosciences
- Jiachen Biotechnology Ltd.
- +38 more
Organization Involved with Phase 1 Indications (26)
- Ligand Pharmaceuticals
- Dicerna Pharmaceuticals, Inc.
- Enanta Pharmaceuticals
- Hengrui Therapeutics, Inc.
- Inovio Pharmaceuticals
- Novira Therapeutics, Inc.
- PowderMed
- Dynavax Technologies Corporation
- Genexine, Inc.
- Transgene
- TetraLogic Pharmaceuticals
- Cathay General Hospital
- Siriraj Hospital
- University of Oklahoma
- City University of Hong Kong
- Maharaj Nakorn Chiang Mai Hospital
- University of Amsterdam
- IDT Australia Ltd.
- Department of Veteran Affairs
- CPR Pharma Services Pty Ltd, Australia
- Johnson and Johnson
- Scientia Clinical Research Limited Sydney
- Antios Therapeutics, Inc
- Nucorion Pharmaceuticals, Inc.
- PharmaEssentia Corp.
- Aligos Therapeutics
Organization Involved with Other Experimental Indications (18)
- Organic India
- Hepa C
- Triệu, Nguyễn Thị, M.D.
- Changhai Hospital
- Chulalongkorn University
- Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
- Indian Council of Medical Research
- Maimonides Medical Center
- University of Michigan
- Institute of Liver and Biliary Sciences, India
- Xiamen University
- Zhengzhou University
- University of California, Los Angeles
- Narayana Hrudayalaya Limited
- Tran Minh Duc, Dr.
- Lady Hardinge Medical College
- Institut Hospital del Mar d'Investigacions Mèdiques
- Universidad Carlos III Madrid